Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Common Stock Valuation Ratios (Price Multiples) 

Microsoft Excel

Current Valuation Ratios

Biogen Inc., current price multiples

Microsoft Excel
Biogen Inc. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc. Pharmaceuticals, Biotechnology & Life Sciences Health Care
Selected Financial Data
Current share price (P) $273.56
No. shares of common stock outstanding 144,001,404
Growth rate (g) 29.64%
 
Earnings per share (EPS) $10.81
Next year expected EPS $14.01
Operating profit per share $19.73
Sales per share $76.26
Book value per share (BVPS) $75.67
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 25.32 78.15 39.21 37.30 69.86 289.60 26.69 11.87 17.97 13.39 25.58 22.96 22.86
Price to next year expected earnings 19.53 179.31 30.88 34.19 55.00 24.03 17.10 10.83 22.32 21.25 20.96
Price-earnings-growth (PEG) 0.85 1.45 4.10 2.59 2.42 3.56 0.57 1.75 2.84 2.52
Price to operating profit (P/OP) 13.87 36.59 22.09 29.90 57.36 83.64 18.04 10.21 11.63 14.81 22.09 19.88 18.92
Price to sales (P/S) 3.59 5.94 5.01 1.98 6.09 16.43 4.86 4.23 3.17 2.27 4.16 3.78 10.71 5.36 2.84
Price to book value (P/BV) 3.62 100.55 27.29 5.85 2.94 52.13 7.19 5.25 4.39 1.64 2.01 3.27 7.19 6.82 5.43

Based on: 10-K (reporting date: 2021-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Biogen Inc., historical price multiples

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Price to earnings (P/E) 20.79 10.02 9.97 14.79 28.83
Price to operating profit (P/OP) 11.39 8.81 8.34 11.13 13.70
Price to sales (P/S) 2.95 2.98 4.08 4.87 5.96
Price to book value (P/BV) 2.97 3.75 4.40 5.03 5.80

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The financial ratios exhibit several notable trends over the five-year period examined.

Price to Earnings (P/E) Ratio
The P/E ratio shows a significant decline from 28.83 in 2017 to a low point near 10 in 2019 and 2020, indicating a substantial reduction in market valuation relative to earnings during these years. However, in 2021, this ratio rebounds sharply to 20.79, suggesting renewed investor confidence or improved earnings expectations.
Price to Operating Profit (P/OP) Ratio
This ratio declines steadily from 13.7 in 2017 to 8.34 in 2019, reflecting a reduction in market price relative to operating profits. There is a slight increase in 2020 to 8.81 and a more pronounced rise in 2021 to 11.39, indicating some recovery in the valuation relative to operating profit but still below the 2017 level.
Price to Sales (P/S) Ratio
The P/S ratio experiences a continuous downward trend from 5.96 in 2017 to approximately 2.95 in 2021. This steady decrease suggests a declining market valuation relative to sales, which may indicate market concerns about sales growth or profitability margins in the sector.
Price to Book Value (P/BV) Ratio
The P/BV ratio also decreases progressively from 5.8 in 2017 to 2.97 in 2021. This trend reflects a declining market valuation in relation to the company's book value, which could signal investor caution regarding asset valuation or future returns on equity.

Overall, the data depicts a general downward trend in valuation multiples from 2017 through 2020, followed by some recovery in earnings and operating profit-related ratios in 2021, while sales and book value-related ratios continue their decline. This pattern suggests fluctuating investor sentiment, with increased optimism in recent periods regarding earnings and profitability, but persistent skepticism about sales growth and asset valuation.


Price to Earnings (P/E)

Biogen Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 146,962,793 152,335,731 174,064,011 196,708,784 211,562,686
Selected Financial Data (US$)
Net income attributable to Biogen Inc. (in thousands) 1,556,100 4,000,600 5,888,500 4,430,700 2,539,100
Earnings per share (EPS)2 10.59 26.26 33.83 22.52 12.00
Share price1, 3 220.17 263.25 337.24 333.24 346.00
Valuation Ratio
P/E ratio4 20.79 10.02 9.97 14.79 28.83
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. 22.07 40.17
Amgen Inc. 21.05 18.82
Bristol-Myers Squibb Co. 20.92
Danaher Corp. 29.94 44.49
Eli Lilly & Co. 40.66 31.95
Gilead Sciences Inc. 12.36 641.48
Johnson & Johnson 20.93 28.92
Merck & Co. Inc. 14.78 26.72
Pfizer Inc. 11.76 19.62
Regeneron Pharmaceuticals Inc. 8.37 15.09
Thermo Fisher Scientific Inc. 27.35 27.89
Vertex Pharmaceuticals Inc. 26.55 20.18
P/E Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 19.27 34.89
P/E Ratio, Industry
Health Care 21.35 30.75

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
EPS = Net income attributable to Biogen Inc. ÷ No. shares of common stock outstanding
= 1,556,100,000 ÷ 146,962,793 = 10.59

3 Closing price as at the filing date of Biogen Inc. Annual Report.

4 2021 Calculation
P/E ratio = Share price ÷ EPS
= 220.17 ÷ 10.59 = 20.79

5 Click competitor name to see calculations.


The financial data reveals several notable trends over the five-year period ending in 2021.

Share Price
The share price exhibited a declining trend overall. Starting at 346 US$ at the end of 2017, it decreased marginally in 2018 and 2019, before experiencing a sharper decline in the last two years, falling to 220.17 US$ by the end of 2021. This represents a significant reduction in market valuation over the period.
Earnings Per Share (EPS)
The EPS showed considerable volatility. It began at 12 US$ in 2017, then dramatically increased to 22.52 US$ in 2018 and surged further to 33.83 US$ in 2019. However, following this peak, EPS declined sharply to 26.26 US$ in 2020 and further plummeted to 10.59 US$ in 2021, reaching a level below that observed in 2017. This downward trend in the last two years indicates deteriorating profitability per share.
Price-to-Earnings (P/E) Ratio
The P/E ratio displayed significant fluctuations. It started relatively high at 28.83 in 2017 and then decreased steadily to a low of 9.97 in 2019, suggesting that the market valuation per unit of earnings was becoming more conservative despite rising EPS. In 2020, the P/E ratio remained stable around 10.02 but then increased notably to 20.79 by the end of 2021. This increase in P/E, despite the declining EPS and share price, might imply a change in market sentiment or expectations about future earnings potential.

In summary, the period featured rising earnings until 2019, followed by a marked decline thereafter. The share price trend largely mirrored the declining earnings in the last two years but started from a peak in 2017. The P/E ratio’s initial decline suggests increasing earnings outpacing price adjustments, but its later rise indicates a more complex valuation dynamic as earnings fell. This pattern may warrant further investigation into underlying operational factors and market perceptions influencing the valuation.


Price to Operating Profit (P/OP)

Biogen Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 146,962,793 152,335,731 174,064,011 196,708,784 211,562,686
Selected Financial Data (US$)
Income from operations (in thousands) 2,840,700 4,550,100 7,042,600 5,888,600 5,344,200
Operating profit per share2 19.33 29.87 40.46 29.94 25.26
Share price1, 3 220.17 263.25 337.24 333.24 346.00
Valuation Ratio
P/OP ratio4 11.39 8.81 8.34 11.13 13.70
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. 14.21 16.32
Amgen Inc. 16.24 14.96
Bristol-Myers Squibb Co. 19.84
Danaher Corp. 25.14 36.91
Eli Lilly & Co. 35.70 32.66
Gilead Sciences Inc. 7.76 19.38
Johnson & Johnson 18.68 21.84
Merck & Co. Inc. 15.39 23.89
Pfizer Inc. 12.74 21.12
Regeneron Pharmaceuticals Inc. 7.55 14.82
Thermo Fisher Scientific Inc. 21.07 22.81
Vertex Pharmaceuticals Inc. 22.35 19.16
P/OP Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 16.68 25.95
P/OP Ratio, Industry
Health Care 17.67 22.32

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 2,840,700,000 ÷ 146,962,793 = 19.33

3 Closing price as at the filing date of Biogen Inc. Annual Report.

4 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 220.17 ÷ 19.33 = 11.39

5 Click competitor name to see calculations.


Share Price Trend
The share price experienced a gradual decline over the five-year period. Starting from $346 at the end of 2017, it decreased slightly to $333.24 in 2018 and remained relatively stable at $337.24 in 2019. However, a more pronounced decline occurred in the following years, with the price dropping to $263.25 in 2020 and further to $220.17 by the end of 2021.
Operating Profit per Share (OPPS) Trend
The operating profit per share showed improvement from 2017 through 2019, increasing from $25.26 to a peak of $40.46 in 2019. This indicates enhanced operational performance during this period. However, there was a notable decline in the subsequent years, with the OPPS falling to $29.87 in 2020 and further decreasing to $19.33 by the end of 2021, signifying a reduction in operating profitability per share.
Price to Operating Profit Ratio (P/OP)
The P/OP ratio, representing the share price relative to operating profit per share, showed a downward trend from 2017 to 2019, moving from 13.7 to a low of 8.34. This suggests that the stock became more attractively valued relative to its operating profitability during this period. In 2020, the ratio increased slightly to 8.81, and then more substantially to 11.39 in 2021, indicating that the share price declined less proportionally compared to the drop in operating profits, or that the market assigned a higher multiple to the remaining operating profit in 2021.
Overall Analysis
The data reveals that the company experienced an initial period of improving operating profitability per share coupled with a declining share price resulting in lower valuation multiples, which could imply increased operational efficiency or market undervaluation. However, from 2020 onwards, both the operating profit per share and share price declined, with the profitability decline outpacing the share price reduction as evidenced by an increased P/OP ratio. This reversal could suggest operational challenges or changing market perceptions impacting profitability more significantly than share price, potentially reflecting broader business or economic conditions during that timeframe.

Price to Sales (P/S)

Biogen Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 146,962,793 152,335,731 174,064,011 196,708,784 211,562,686
Selected Financial Data (US$)
Revenue (in thousands) 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Sales per share2 74.72 88.26 82.60 68.39 58.02
Share price1, 3 220.17 263.25 337.24 333.24 346.00
Valuation Ratio
P/S ratio4 2.95 2.98 4.08 4.87 5.96
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. 4.53 4.05
Amgen Inc. 5.10 5.64
Bristol-Myers Squibb Co. 3.16 3.16
Danaher Corp. 6.37 7.01
Eli Lilly & Co. 8.01 8.06
Gilead Sciences Inc. 2.85 3.24
Johnson & Johnson 4.66 5.15
Merck & Co. Inc. 3.96 3.93
Pfizer Inc. 3.15 4.42
Regeneron Pharmaceuticals Inc. 4.20 6.24
Thermo Fisher Scientific Inc. 5.39 5.52
Vertex Pharmaceuticals Inc. 8.21 8.82
P/S Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.50 4.90
P/S Ratio, Industry
Health Care 2.65 2.59

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= 10,981,700,000 ÷ 146,962,793 = 74.72

3 Closing price as at the filing date of Biogen Inc. Annual Report.

4 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 220.17 ÷ 74.72 = 2.95

5 Click competitor name to see calculations.


The analysis of the presented financial data reveals several notable trends over the five-year period from the end of 2017 to the end of 2021. The share price demonstrates a consistent decline over this timeframe, indicating a reduction in market valuation. Starting at 346 US dollars at the end of 2017, the share price fell gradually each year, ending at 220.17 US dollars by the end of 2021. This trend suggests potential challenges or changes in market perception affecting the company’s equity value.

In contrast, sales per share exhibited an upward trajectory in the initial years, rising from 58.02 US dollars in 2017 to a peak of 88.26 US dollars in 2020. However, in 2021, there was a noticeable decline to 74.72 US dollars. The initial growth in sales per share points to improved operational performance or revenue growth during the early part of the period, but the downturn in the final year may indicate emerging difficulties or market headwinds impacting sales.

The price-to-sales (P/S) ratio consistently declined throughout the period covered. Starting at a high of 5.96 in 2017, it decreased steadily to 2.95 by the end of 2021. This decline can be interpreted as the market assigning a lower valuation per unit of sales over time, which might reflect evolving investor expectations, shifts in profitability, or increased risk perceptions. The trend aligns with the observed decrease in share price despite earlier growth in sales per share.

Summary of key trends:
The share price dropped significantly from 346 to 220.17 US dollars over five years, robustly declining each year after 2018.
Sales per share increased markedly from 58.02 to 88.26 US dollars by 2020, before falling back to 74.72 US dollars in 2021.
The price-to-sales ratio showed a continuous decrease from 5.96 to 2.95, indicating a lowering market valuation relative to the company’s sales.

Overall, while sales per share experienced growth initially, the sustained decline in share price and P/S ratio suggests that market confidence weakened over time, possibly reflecting concerns beyond sales performance alone. The decline in sales per share in the final year further supports the notion of emerging operational challenges or external pressures impacting the company’s financial outlook.


Price to Book Value (P/BV)

Biogen Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
No. shares of common stock outstanding1 146,962,793 152,335,731 174,064,011 196,708,784 211,562,686
Selected Financial Data (US$)
Total Biogen Inc. shareholders’ equity (in thousands) 10,896,200 10,700,300 13,343,200 13,039,600 12,612,800
Book value per share (BVPS)2 74.14 70.24 76.66 66.29 59.62
Share price1, 3 220.17 263.25 337.24 333.24 346.00
Valuation Ratio
P/BV ratio4 2.97 3.75 4.40 5.03 5.80
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. 16.53 14.18
Amgen Inc. 18.51 14.53
Bristol-Myers Squibb Co. 4.07 3.55
Danaher Corp. 4.16 3.93
Eli Lilly & Co. 25.28 35.07
Gilead Sciences Inc. 3.65 4.33
Johnson & Johnson 5.90 6.72
Merck & Co. Inc. 5.05 7.46
Pfizer Inc. 3.35 2.98
Regeneron Pharmaceuticals Inc. 3.60 4.81
Thermo Fisher Scientific Inc. 5.18 5.15
Vertex Pharmaceuticals Inc. 6.16 6.30
P/BV Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.72 5.99
P/BV Ratio, Industry
Health Care 5.07 4.90

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Data adjusted for splits and stock dividends.

2 2021 Calculation
BVPS = Total Biogen Inc. shareholders’ equity ÷ No. shares of common stock outstanding
= 10,896,200,000 ÷ 146,962,793 = 74.14

3 Closing price as at the filing date of Biogen Inc. Annual Report.

4 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 220.17 ÷ 74.14 = 2.97

5 Click competitor name to see calculations.


Share Price Trend
The share price exhibited a declining trend over the analyzed period. Starting from a high of 346 US dollars at the end of 2017, the price slightly decreased to approximately 333.24 US dollars by the end of 2018, then marginally increased to 337.24 US dollars at the end of 2019. Afterward, the price experienced a more pronounced drop to 263.25 US dollars in 2020, followed by a further decline to 220.17 US dollars by the end of 2021.
Book Value per Share (BVPS) Trend
The book value per share generally demonstrated an upward trajectory despite some fluctuations. It grew from 59.62 US dollars in 2017 to 66.29 US dollars in 2018, with a continued increase to 76.66 US dollars by the end of 2019. However, it decreased to 70.24 US dollars in 2020 before recovering somewhat to 74.14 US dollars in 2021.
Price-to-Book Value (P/BV) Ratio Trend
The P/BV ratio presented a clear declining pattern over the five-year period, indicating a decreasing market valuation relative to the company's book value. Starting at 5.8 in 2017, the ratio declined steadily each year to 5.03 in 2018, 4.4 in 2019, 3.75 in 2020, and further down to 2.97 in 2021.
Insights and Implications
The decreasing share price accompanied by a generally increasing book value per share has led to a substantial reduction in the P/BV ratio over time. This trend may suggest that the market is valuing the company's assets more conservatively, or that investor sentiment toward the company has become less optimistic. The drop in share price despite an increase in book value per share could indicate concerns about future earnings potential, external factors affecting market perception, or increased risk perceptions. The drop in book value per share in 2020 might reflect a temporary financial setback during that year, which partially recovered by 2021. Overall, the decreasing P/BV ratio points to a shift toward a more value-oriented appraisal by the market.